Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 2/20 | 0.40 |
| ▸ | FNTB | P49356 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | REN | P00797 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6056476 | 0.91 | FNTA (0.39) | FNTAFNTBTSHR | |
| SCHEMBL7628732 | 0.84 | FNTA (0.45) | FNTAFNTBALDH1A1CYP2C9TSHR | |
| SCHEMBL6056363 | 0.83 | ALDH1A1 (0.35) | FNTAFNTBALDH1A1L3MBTL1USP2 | |
| SCHEMBL31199201 | 0.80 | L3MBTL1 (0.43) | ALDH1A1L3MBTL1 | |
| SCHEMBL6056422 | 0.76 | EGFR (0.43) | FNTAFNTBALDH1A1L3MBTL1TSHR | |
| SCHEMBL7997081 | 0.76 | FNTA (0.37) | FNTAFNTBALDH1A1L3MBTL1USP2 | |
| SCHEMBL6056440 | 0.76 | FNTA (0.47) | FNTAFNTB | |
| SCHEMBL6056420 | 0.75 | KMT2A (0.35) | FNTAFNTBALDH1A1USP2TSHR | |
| SCHEMBL6056540 | 0.74 | FNTA (0.51) | FNTAFNTBL3MBTL1TSHR | |
| SCHEMBL8330806 | 0.74 | FNTA (0.46) | FNTAFNTBALDH1A1L3MBTL1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0725650-A4 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 1999-02-03 | — | — | EP | claimed |
| EP-0836383-A1 | COMBINATIONS OF INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1998-04-22 | — | — | EP | claimed |
| WO-1997001275-A1 | COMBINATIONS OF INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-01-16 | — | — | WO | claimed |
| EP-0725650-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO. INC. (US) | 1996-08-14 | — | — | EP | claimed |
| WO-1995009001-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1995-04-06 | — | — | WO | claimed |
| WO-2006017369-A2 | USE OF A FARNESYL TRANSFERASE INHIBITOR IN THE TREATMENT OF VIRAL INFECTIONS | GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-02-16 | — | — | WO | disclosed |
| US-20020006967-A1 | METHODS OF TREATMENT OF OCULAR NEOVASCULARIZATION | CAMPOCHIARO PETER A (US) | 2002-01-17 | — | — | US | disclosed |
| US-6160015-A | ADMINISTERING TO MAMMAL A FARNESYL PROTEIN TRANSFERASE INHIBITOR | UNIVERSITY OF CINCINNATI (US) | 2000-12-12 | — | — | US | disclosed |
| EP-0840605-A4 | COMPOUNDS USEFUL IN THE TREATMENT OF NEUROFIBROMATOSIS | UNIV CINCINNATI (US) | 2000-05-10 | — | — | EP | disclosed |
| EP-0725650-A4 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 1999-02-03 | — | — | EP | disclosed |
| WO-1998057654-A1 | METHODS FOR TREATMENT OF OCULAR NEOVASCULARIZATION | JOHNS HOPKINS UNIVERSITY (US) | 1998-12-23 | — | — | WO | disclosed |
| EP-0840605-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF NEUROFIBROMATOSIS | University of Cincinnati (US) | 1998-05-13 | — | — | EP | disclosed |
| EP-0836383-A1 | COMBINATIONS OF INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1998-04-22 | — | — | EP | disclosed |
| WO-1997002817-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF NEUROFIBROMATOSIS | UNIVERSITY OF CINCINNATI (US) | 1997-01-30 | — | — | WO | disclosed |
| WO-1997001275-A1 | COMBINATIONS OF INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-01-16 | — | — | WO | disclosed |
| US-5576293-A | TETRAPEPTIDES, ANTICARCINOGENIC AGENTS | MERCK & CO., INC. (US) | 1996-11-19 | — | — | US | disclosed |
| EP-0725650-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO. INC. (US) | 1996-08-14 | — | — | EP | disclosed |
| WO-1995009001-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1995-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006967-A1 | METHODS OF TREATMENT OF OCULAR NEOVASCULARIZATION | GGT1, FNTA, PIGO | FNTA 2/4885FNTB 11/4885ALDH1A1 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.